Tordrup D, Hutin Y, Stenberg K, et al. - Experts estimated the incremental commodity cost of adding scaled up interventions for testing and treatment of hepatitis to the WHO's investment scenarios. The 67 countries included in this analysis involved 230 million and 52 million people living with hepatitis B virus and hepatitis C virus (HCV), respectively. A total of 3,250 million and 58.2 million people, respectively, would be tested and would be treated, under the progress scenario. In contrast, 11,631 million and 93.8 million people would be tested and would be treated, averting 4.5 million premature deaths and leading to a gain of 51.5 million healthy life-years by 2030 under the ambitious scenario. Nevertheless, the additional cost of the ambitious scenario would rise to $118 billion, if affordable HCV medicines continued to be inaccessible in 13 countries where medicine patents are protected. From 2016–2030, hepatitis elimination would account for a 1.5% rise to the WHO ambitious healthcare strengthening scenario costs, avert an additional 4.6% premature deaths, and add an additional 9.6% healthy life-years.